导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.20% | 4168/4773 |
| 近一周 | -3.01% | 4479/5465 |
| 近一月 | -3.10% | 2172/5421 |
| 近一季 | -5.50% | 2089/5231 |
| 近半年 | -13.13% | 3863/4920 |
| 近一年 | -16.86% | 3848/4394 |
| 近两年 | 20.06% | 2648/2954 |
| 近三年 | 11.81% | 1711/2253 |
| 成立以来 | 113.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.59% 4308/4961 |
-7.26% 3775/5312 |
- - |
- - |
| 2025 | 11.72% 2729/4813 |
5.13% 819/3635 |
-4.60% 3485/4076 |
14.23% 2934/4524 |
-2.49% 3155/4813 |
| 2024 | 26.86% 211/3463 |
5.57% 349/2808 |
-1.37% 1049/3014 |
18.59% 981/3129 |
2.73% 897/3463 |
| 2023 | -5.77% 776/2656 |
3.56% 1166/2280 |
-1.27% 467/2385 |
-1.91% 600/2515 |
-6.04% 1607/2655 |
| 2022 | -17.39% 585/2207 |
-19.42% 1456/1919 |
17.49% 122/2016 |
-14.61% 1122/2113 |
2.19% 1012/2208 |
| 2021 | 0.84% 703/1822 |
-2.20% 596/1255 |
4.21% 911/1330 |
-7.30% 1041/1466 |
6.73% 207/1822 |
| 2020 | 39.40% 334/1250 |
-10.38% 774/1028 |
18.26% 347/1067 |
15.95% 184/1164 |
13.43% 361/1184 |
| 2019 | 31.95% 454/1092 |
26.61% 389/754 |
-6.79% 523/804 |
2.03% 332/850 |
9.59% 218/918 |
| 2018 | -33.19% 546/834 |
- - |
- - |
- - |
-12.60% 462/691 |
| 2017 | 5.17% 361/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.11% 371/605 |
- - |
- - |
- - |
- - |
| 2015 | 46.50% 29/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证全指可选消费ETF VS. 长安沪深300非周期A(740101) |